Recruiting Phase 1 2025-522243-17-00

A Phase I study to evaluate the safety and efficacy of L19IL2 in combination with ruxolitinib in patients with advanced solid tumors.

Phase 1 – testing safety in a small group of people

Conditions: Advanced solid tumors specifically: • metastatic clear cell renal carcinoma • proficient mismatch repair / microsatellite stable (pMMR/MSS) BRAF-V600E-mutant negative colorectal carcinoma • locally advanced or metastatic pancreatic adenocarcinoma

Sponsor: Philogen S.p.A.

trial.available_in:

БГ

Overview

Trial status: Authorised

Who can participate

Age group: 65+ years, 18-64 years Gender: Female, Male Target enrollment: 96 participants

Locations 1

Italy (1)

Status

Recruiting

Phase

Phase 1

Study type

INTERVENTIONAL

Sex

Male and female

Minimum age

18 Years

Healthy volunteers

Start date

22.12.2025

Registry ID

2025-522243-17-00

Source

euclinicaltrials.eu

trial.inquiry_btn

Information is automatically extracted from ClinicalTrials.gov. Consult your doctor before taking action.